Source: Virtual Congress 2021 – Clinical year in review



Rating:

Share or cite this content

Citations should be made in the following way:
M. Barrecheguren Fernandez (Barcelona, Spain). COPD: implementing biomarkers to improve prognosis. Virtual Congress 2021 – Clinical year in review

Member's Comments

No comment yet.

Related content which might interest you: COPD detected with screening: impact on patient management and prognosis Source: Eur Respir J 2014; 44: 1571-1578 Year: 2014 Do cardiac biomarkers predict long-term outcomes from exacerbations of COPD? Source: International Congress 2017 – Highlights on clinical problems in COPD Year: 2017 COPD: algorithms and clinical management Source: Eur Respir J, 50 (5) 1701733; 10.1183/13993003.01733-2017 Year: 2017 Which tools to improve early diagnosis of COPD in primary care? Source: Annual Congress 2009 - Methodological aspects of asthma and COPD epidemiology Year: 2009 Factors predicting clinically improved health status in COPD patients after pulmonary rehabilitation Source: Annual Congress 2011 - What do individuals know about their disease? Educational needs, the psychological impact of chronic respiratory disease and health-related quality of life Year: 2011 COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging Source: Eur Respir J, 52 (5) 1801570; 10.1183/13993003.01570-2018 Year: 2018 Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Source: Eur Respir J 2016; 48: 279-281 Year: 2016 Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Source: Eur Respir J 2016; 48: 281-282 Year: 2016 Clinical phenotyping of COPD patients: a simple tool with prognosis value Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 How to better assess and predict disease progression and treatment response: home-based spirometry, biomarkers or …? Source: International Congress 2019 – High-tech in interstitial lung diseases: just hype and gadgets? Year: 2019 Cluster phenotyping as an approach to identify COPD patients at risk of poor prognosis. Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 What is the best biomarker of COPD stability? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Educating cardiologists on COPD management to improve CVD outcomes Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 COPD related fatigue (COPD-RF) as a patient centred outcome tool in COPD: Various predictors and its correlation with other outcome parameters Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Does aging affect the outcome of comprehensive pulmonary rehabilitation in patients with COPD? Source: Eur Respir J 2003; 22: Suppl. 45, 426s Year: 2003 Dynapenia in COPD exacerbation: what is its relevance in clinical prognosis? Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy Year: 2017 Determining the best diagnostic biomarker for sepsis and prognosis assessment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Can nutrition improve performance in COPD? Source: International Congress 2015 – Nutrition in chronic respiratory disease Year: 2015